Forian (Forian) Change In Receivables : $0.34 Mil (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Forian Change In Receivables?

Forian's change in receivables for the quarter that ended in Mar. 2024 was $-1.59 Mil. It means Forian's Accounts Receivable increased by $1.59 Mil from Dec. 2023 to Mar. 2024 .

Forian's change in receivables for the fiscal year that ended in Dec. 2023 was $0.36 Mil. It means Forian's Accounts Receivable declined by $0.36 Mil from Dec. 2022 to Dec. 2023 .

Forian's Accounts Receivable for the quarter that ended in Mar. 2024 was $4.27 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Forian's Days Sales Outstanding for the three months ended in Mar. 2024 was 79.86.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Forian's liquidation value for the three months ended in Mar. 2024 was $19.69 Mil.

Forian Change In Receivables Historical Data

The historical data trend for Forian's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Forian Change In Receivables Chart

Forian Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

-0.22

-2.50

-1.97

0.36

Forian Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial												-1.57	-0.01	1.46	0.49	-1.59

Forian Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.34 Mil.

Forian (NAS:FORA) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Forian's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	4.268	/	4.877	*	91
=	79.86

2. In Ben Graham's calculation of liquidation value, Forian's accounts receivable are only considered to be worth 75% of book value:

Forian's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	47.435	-	30.95	+	0.75 * 4.268	+	0.5 * 0
=	19.69

Forian Change In Receivables Related Terms

Thank you for viewing the detailed overview of Forian's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Forian (Forian) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Forian Inc (NAS:FORA) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

41 University Drive, Suite 400, Newtown, PA, USA, 18940

Website

https://www.forian.com

Forian Inc provides a suite of SaaS solutions, data management capabilities, and proprietary data and analytics to optimize and measure operational, clinical, and financial performance for customers within the traditional and emerging life sciences, healthcare payer and provider segments, as well as cannabis dispensaries, manufacturers, cultivators, and regulators.

Executives

Martin J Wygod	director	P.O. BOX 676306, RANCHO SANTA FE CA 92067
Trotman Stanley S Jr	director
Max C Wygod	director, officer: Executive Chairman	41 UNIVERSITY PLACE, SUITE 400, NEWTOWN PA 18940
Max Wygod Family Dynasty Trust	10 percent owner	41 UNIVERSITY DRIVE, SUITE 400, NEWTOWN PA 18940
Michael Vesey	officer: Chief Financial Officer	4041-T HADLEY ROAD, S. PLAINFIELD NJ 07080
Jennifer Hajj	director	41 UNIVERSITY PLACE, SUITE 400, NEWTOWN PA 18940
Kristiina Md Vuori	director	C/O WEBMD HEALTH CORP., 111 EIGHTH AVENUE, NEW YORK NY 10011
Scott Matthew Ogur	director	C/O HELIX TCS, INC., 10200 E. GIRARD AVENUE, SUITE B420, DENVER CO 80231
Farren Clifford A Jr	officer: Chief Financial Officer	C/O SYNAVANT INC, 3445 PEACHTREE ROAD NE SUITE 1400, ATLANTA GA 30326
Adler Mark J Md	director
Ian Banwell	director	P.O. BOX 34004, CHARLOTTE NC 28234
Shahir Kassam-adams	director	41 UNIVERSITY PLACE, SUITE 400, NEWTOWN PA 18940
Adam H Dublin	director, officer: Chief Strategy Officer	41 UNIVERSITY PLACE, SUITE 400, NEWTOWN PA 18940
Daniel J Barton	director, officer: Chief Executive Officer	41 UNIVERSITY PLACE, SUITE 400, NEWTOWN PA 18940
Alyssa F Varadhan	director	41 UNIVERSITY PLACE, SUITE 400, NEWTOWN PA 18940